The Institute for Clinical and Health Effectiveness (IECS), the Pan American Health Organization (PAHO/WHO) and the USAID Office within the framework of the Integrated Maternal and Child Health Program conducted an economic evaluation of the use of oxytocin in the Uniject ™ injection system versus the standard use in ampoules for the prevention of postpartum hemorrhage in the active management of the third stage of labor in Latin America and the Caribbean.
To access the full report in PDF format, click on the following link: Uniject-report-Spanish
It is possible to obtain the results of the economic evaluation of the Unject device for each of the countries included in the study and/or modify the suggested inputs according to your personal criteria or considerations using the platform available below.
Postpartum haemorrhage (PPH) is a leading cause of maternal death worldwide and despite strong evidence for the efficacy of oxytocin use in preventing PPH, its uptake remains low. The Uniject (OiU) pre-filled oxytocin injection system has the potential to increase oxytocin use due to its ease of application but at a higher cost than the current ampoule strategy.
The objective of this study is to evaluate the cost-effectiveness of replacing the use of oxytocin in ampoules with OiU in Latin America and the Caribbean. To this end, an epidemiological model was constructed that estimated the impact of this intervention on health system costs, the incidence of PPH, and quality-adjusted life years (QALYs) in each country.
The results of the economic evaluation as well as the technical description of the model can be found here. This web platform was built as a tool to allow decision makers and researchers in each country to calibrate the economic model to their context, with the possibility of selecting new values for the different parameters, thus obtaining results more adjusted to the local reality of their country or region.
This project was funded through a research contract between the Institute for Clinical Effectiveness and Health (IECS), the Pan American Health Organization (PAHO/WHO), and the Maternal and Child Health Integrated Program (MCHIP) of the United States Agency for International Development (USAID). USAID funding has been made possible by the generous support of the American people under the terms of Leader with Associates Cooperative Agreement GHS-A-00-08-00002-00. The contents are the responsibility of IECS and MCHIP and do not necessarily reflect the views of USAID, the United States Government, or PAHO.